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line was designated as the index date. Patients’ pharmacy claims
were followed for one year after their index dates. Adherence
with RAS therapy was measured by medication possession ratio
(MPR). Prescription copay was measured by a ﬂat dollar amount
paid for RAS therapy, normalized at days of supply level. Regres-
sion analyses were adopted to analyze the effects of copay on
adherence with RAS therapy. Other control variables included
age, gender, comorbidities, concomitant medications (b-blockers,
statins, calcium channel blockers), and the step-therapy care
program. RESULTS: The results show that of the 799 heart
failure patients, 457 (57%) received RAS therapy. 48% of the
457 patients were adherent (MPR  0.8), 22% were partially
adherent (0.5 MPR < 0.8) and 30% were non-adherent
(MPR < 0.5). Prescription copay had a signiﬁcant negative effect
on adherence, which meant higher copayment led to lower adher-
ence rates such that for every $1 increase in prescription copay,
adherence decreased by 9%. Of the controlling variables, only
age had a positive impact on adherence where older individuals
were more compliant with RAS therapy than younger people.
CONCLUSION: Approximately 4 out of 10 patients did not
receive recommended pharmacotherapy with RAS agents after a
heart failure event. Furthermore, only half of those patients who
received RAS therapy were considered adherent. Higher prescrip-
tion copay was associated with lower adherence to RAS therapy.
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OBJECTIVE: African Americans (AAs) have higher prevalence
of hypertension and worse cardiovascular and renal outcomes
than Caucasians. Previous studies have shown that adherence to
antihypertensive medications is lower in African Americans
than Caucasians. Limited information is available on behavioral
factors associated with medication adherence in African
Americans. Therefore, our objective was to determine the bar-
riers and motivators associated with adherence to antihyperten-
sive medications and blood pressure control among African
Americans living in Alabama. METHODS: A cross-sectional
study sampled adult AAs outpatients with a diagnosis of hyper-
tension that were receiving at least one antihypertensive medi-
cation, were residents of Jefferson County and had signed the
informed consent. A face to face interview was conducted by
three previously trained and certiﬁed interviewers that adminis-
tered a computer-assisted structured questionnaire to collect
survey data on demographics, medical history and behavioral
measures (medication adherence, self-efﬁcacy, and barriers and
motivators). RESULTS: Seven hundred and forty eight AAs par-
ticipated: 71% women, 85% older than 45 years of age, 59%
ﬁnished high school, and 87% had annual family income
<$5000. Forty percent of participants adhered to antihyperten-
sive medications. There were statistically signiﬁcant differences
in diastolic blood pressure between adherent (80  14) and
non-adherent patients (83  15, p = 0.03). Compared to non-
adherent patients, more adherent patients took their medica-
tions as directed because they felt they were doing something to
reduce their blood pressure (p = 0.030), felt their disease was
under control (p = 0.001) and felt more responsible (p = 0.033).
A higher proportion of adherent patients overcome barriers
such as taking medications when they were busy at home
(p = 0.0001), when they were working (p = 0.001), or when
they were in public places (p = 0.001). CONCLUSION: Adher-
ent patients were able to overcome barriers for medication
adherence. Interventions focused on motivators have the
potential for improving blood pressure control in high-risk
populations.
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OBJECTIVE: The main purpose of this study was to evaluate the
impact of Statin Step Care (SC) Program on patient compliance.
METHODS: Using a pre-post self case-control approach, pre-
scription records were obtained from de-identiﬁed pharmacy
claims database maintained by a large pharmacy beneﬁt manager
(PBM). To be included in the analysis, SC program enrollees were
deﬁned as having at least one generic statin prescription on or
after May 1, 2007 (index date) and any brand name statin
prescription history before the index date. The case group was
comprised of statin prescription records of enrollees four months
before and after the index date. All eligible patients were also
checked for their continuous enrollment during the study period.
Statin prescription records of the same enrollees group in a
similar timeframes of 2006 were obtained as a control group.
Compliance was assessed in terms of medication possession ratio
(MPR), deﬁned as sum of days that patient possessed any statin
medication divided by the total number of days in the follow-up
period. MPR was calculated for the pre and post periods and
compared using paired t-test. RESULTS: A total of 4122 claims
and 451 eligible enrollees were included in the analysis. For the
study group, mean MPR increased from 0.8347 to 0.8571
(p-value = 0.0304) from the pre-period to the post-period.
However, in the control group, the mean MPR increased slightly
from 0.8540 to 0.8554 (p-value = 0.8709), and the difference
was not found to be statistically signiﬁcant. CONCLUSION: A
signiﬁcant increase in the MPR was observed in the study group
patients after the statin step care program implementation. The
study suggests that the statin SC program could have improved
the patient compliance. However, further prospective studies are
needed to establish the cause-effect relationship between SC
program and patient compliance.
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OBJECTIVE: To determine the impact of subsequent cardiovas-
cular (CV) events on change in preference-based measures of
HRQL in patients who previously experienced an acute myocar-
dial infarction using data from the VAlsartan IN Acute Myocar-
dial iNfarcTion (VALIANT) trial. METHODS: Patients in the
VALIANT HRQL sub-study completed the EQ-5D, including the
visual analogue scale (VAS) rescaled to 0–1, at baseline, and 6,
12, 20, and 24 months. All EQ-5D assessments from baseline
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